Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants

Cell Reports(2022)10.1016/j.celrep.2022.110812Source: DataRank Database

LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants is a research paper published in Cell Reports (2022). On theSindex it has a DataRank of 0. It has been cited 464 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access464 citations

Download PDF

Cite:

Linked data & code

gen gisaid uniprot pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (14 grants)OA: goldTopics (23)Linked Datasets (16)DataCite Reuse (16)IDs (PubMed, PMC)Annotations (4)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (69)

Stefanie Žentelis,Lingshu Wang ORCID,Denisa Foster,Peter Vaillancourt,Matthew Wiggin

Live enrichment

PubMed:35568025 PMC:PMC9035363

NIAID NIH HHS

Grant: UC7 AI094660

Defense Advanced Research Projects Agency Defense Sciences Office

Grant: D18AC00002

Horizon 2020

Grant: 653316

European Virus Archive goes global

Argonne National Laboratory

Grant: DE-AC02-06CH11357

National Institutes of Health

Grant: 5UC7AI094660-03

National Biocontainment Laboratories (NBLs) Operations Support

Horizon 2020 Framework Programme

National Institute of Allergy and Infectious Diseases

University of Texas Medical Branch

Vaccine Research Center

Eli Lilly and Company

Office of Science

U.S. Department of Defense

U.S. Department of Energy

Defense Advanced Research Projects Agency

goldLicense: https://www.biorxiv.org/about/FAQ#license

Europe_PMChttps://europepmc.org/articles/PMC9035363

Europe_PMChttps://europepmc.org/articles/PMC9035363?pdf=render

https://doi.org/10.1101/2021.04.30.442182

https://www.biorxiv.org/content/biorxiv/early/2022/01/07/2021.04.30.442182.full.pdf

https://doi.org/10.1016/j.celrep.2022.110812

Fields of Study

0301 basic medicine03 medical and health sciences

MeSH Terms

HumansAntibodies, MonoclonalAntibodies, ViralEpitopesAntibodies, NeutralizingSARS-CoV-2COVID-19 Drug Treatment

Keywords

Neutralizing antibodyCovid-19Sars-cov-2Variant Of ConcernCp: MicrobiologyQH301-705.5Antibodies, MonoclonalAntibodies, ViralAntibodies, NeutralizingArticleCOVID-19 Drug TreatmentEpitopesHumansBiology (General)

Sustainable Development Goals

SDG 3: 3. Good health

Additional file 1 of Development of a neutralization monoclonal antibody with a broad neutralizing effect against SARS-CoV-2 variants

10.6084/m9.figshare.24715421.v1figshare

Additional file 1 of Development of a neutralization monoclonal antibody with a broad neutralizing effect against SARS-CoV-2 variants

10.6084/m9.figshare.24715421figshare

Additional file 1 of Engineered clinical-grade mesenchymal stromal cells combating SARS-CoV-2 omicron variants by secreting effective neutralizing antibodies

10.6084/m9.figshare.26614159.v1figshare

Additional file 1 of Engineered clinical-grade mesenchymal stromal cells combating SARS-CoV-2 omicron variants by secreting effective neutralizing antibodies

10.6084/m9.figshare.26614159figshare

Additional file 2 of Engineered clinical-grade mesenchymal stromal cells combating SARS-CoV-2 omicron variants by secreting effective neutralizing antibodies

10.6084/m9.figshare.26614162.v1figshare

Additional file 2 of Engineered clinical-grade mesenchymal stromal cells combating SARS-CoV-2 omicron variants by secreting effective neutralizing antibodies

10.6084/m9.figshare.26614162figshare

Additional file 3 of Engineered clinical-grade mesenchymal stromal cells combating SARS-CoV-2 omicron variants by secreting effective neutralizing antibodies

10.6084/m9.figshare.26614165.v1figshare

Additional file 3 of Engineered clinical-grade mesenchymal stromal cells combating SARS-CoV-2 omicron variants by secreting effective neutralizing antibodies

10.6084/m9.figshare.26614165figshare

Additional file 4 of Engineered clinical-grade mesenchymal stromal cells combating SARS-CoV-2 omicron variants by secreting effective neutralizing antibodies

10.6084/m9.figshare.26614168.v1figshare

Additional file 4 of Engineered clinical-grade mesenchymal stromal cells combating SARS-CoV-2 omicron variants by secreting effective neutralizing antibodies

10.6084/m9.figshare.26614168figshare

Additional file 5 of Engineered clinical-grade mesenchymal stromal cells combating SARS-CoV-2 omicron variants by secreting effective neutralizing antibodies

10.6084/m9.figshare.26614171.v1figshare

Additional file 5 of Engineered clinical-grade mesenchymal stromal cells combating SARS-CoV-2 omicron variants by secreting effective neutralizing antibodies

10.6084/m9.figshare.26614171figshare

Additional file 6 of Engineered clinical-grade mesenchymal stromal cells combating SARS-CoV-2 omicron variants by secreting effective neutralizing antibodies

10.6084/m9.figshare.26614174.v1figshare

Additional file 6 of Engineered clinical-grade mesenchymal stromal cells combating SARS-CoV-2 omicron variants by secreting effective neutralizing antibodies

10.6084/m9.figshare.26614174figshare

Additional file 1 of Cell-based passive immunization for protection against SARS-CoV-2 infection

10.6084/m9.figshare.26636607.v1figshare

Additional file 1 of Cell-based passive immunization for protection against SARS-CoV-2 infection

10.6084/m9.figshare.26636607figshare